A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50
 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
Inclusion Criteria:

 -  Male/female from 16 to 65 years

 -  Well-characterized focal epilepsy or epileptic syndrome according to the International
 League Against Epilepsy (ILAE) classification

 -  History of partial onset seizures

 -  Subjects having at least 4 partial onset seizures during the 4-week Baseline Period
 and at least 2 partial onset seizures during the 3 months prior to Visit 1

 -  Subjects taking 1 or 2 concomitant Antiepileptic drugs (AED(s)) that have been at a
 stable dose.

 Exclusion Criteria:

 -  Seizure type IA non-motor as only seizure type

 -  Seizures occurring only in clusters

 -  Status epilepticus during the last 2 years before Visit 1

 -  History of cerebrovascular accident (CVA)

 -  Presence of any sign suggesting rapidly progressing brain disorder or brain tumor